Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1999 Sep;92(9):456–461. doi: 10.1177/014107689909200906

Pathogenesis and treatment of ANCA-associated systemic vasculitis.

A D Salama 1
PMCID: PMC1297356  PMID: 10645294

Full text

PDF
456

Images in this article

457Figure 2
on p.457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen A., Pusey C., Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 1998 Jul;9(7):1258–1263. doi: 10.1681/ASN.V971258. [DOI] [PubMed] [Google Scholar]
  2. Charles L. A., Caldas M. L., Falk R. J., Terrell R. S., Jennette J. C. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol. 1991 Dec;50(6):539–546. doi: 10.1002/jlb.50.6.539. [DOI] [PubMed] [Google Scholar]
  3. D'Cruz D., Chesser A. M., Lightowler C., Comer M., Hurst M. J., Baker L. R., Raine A. E. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol. 1995 Nov;34(11):1090–1091. doi: 10.1093/rheumatology/34.11.1090. [DOI] [PubMed] [Google Scholar]
  4. De'Oliviera J., Gaskin G., Dash A., Rees A. J., Pusey C. D. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis. 1995 Mar;25(3):380–389. doi: 10.1016/0272-6386(95)90098-5. [DOI] [PubMed] [Google Scholar]
  5. Dolman K. M., Gans R. O., Vervaat T. J., Zevenbergen G., Maingay D., Nikkels R. E., Donker A. J., von dem Borne A. E., Goldschmeding R. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet. 1993 Sep 11;342(8872):651–652. doi: 10.1016/0140-6736(93)91761-a. [DOI] [PubMed] [Google Scholar]
  6. Dolman K. M., van de Wiel B. A., Kam C. M., Kerrigan J. E., Hack C. E., von dem Borne A. E., Powers J. C., Goldschmeding R. Proteinase 3: substrate specificity and possible pathogenetic effect of Wegener's granulomatosis autoantibodies (c-ANCA) by dysregulation of the enzyme. Adv Exp Med Biol. 1993;336:55–60. doi: 10.1007/978-1-4757-9182-2_7. [DOI] [PubMed] [Google Scholar]
  7. Esnault V. L., Testa A., Audrain M., Rogé C., Hamidou M., Barrier J. H., Sesboü R., Martin J. P., Lesavre P. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int. 1993 Jun;43(6):1329–1332. doi: 10.1038/ki.1993.186. [DOI] [PubMed] [Google Scholar]
  8. Ewert B. H., Jennette J. C., Falk R. J. The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis. 1991 Aug;18(2):188–195. doi: 10.1016/s0272-6386(12)80879-1. [DOI] [PubMed] [Google Scholar]
  9. Exley A. R., Carruthers D. M., Luqmani R. A., Kitas G. D., Gordon C., Janssen B. A., Savage C. O., Bacon P. A. Damage occurs early in systemic vasculitis and is an index of outcome. QJM. 1997 Jun;90(6):391–399. doi: 10.1093/qjmed/90.6.391. [DOI] [PubMed] [Google Scholar]
  10. Fauci A. S., Haynes B. F., Katz P., Wolff S. M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76–85. doi: 10.7326/0003-4819-98-1-76. [DOI] [PubMed] [Google Scholar]
  11. Gaskin G., Savage C. O., Ryan J. J., Jones S., Rees A. J., Lockwood C. M., Pusey C. D. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant. 1991;6(10):689–694. doi: 10.1093/ndt/6.10.689. [DOI] [PubMed] [Google Scholar]
  12. Gilligan H. M., Bredy B., Brady H. R., Hébert M. J., Slayter H. S., Xu Y., Rauch J., Shia M. A., Koh J. S., Levine J. S. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med. 1996 Dec 1;184(6):2231–2241. doi: 10.1084/jem.184.6.2231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Giscombe R., Grunewald J., Nityanand S., Lefvert A. K. T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol. 1995 Aug;101(2):213–219. doi: 10.1111/j.1365-2249.1995.tb08341.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Griffith M. E., Lovegrove J. U., Gaskin G., Whitehouse D. B., Pusey C. D. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant. 1996 Mar;11(3):438–443. [PubMed] [Google Scholar]
  15. Griffith M. E., Pusey C. D. HLA genes in ANCA-associated vasculitides. Exp Clin Immunogenet. 1997;14(3):196–205. [PubMed] [Google Scholar]
  16. Heeringa P., Brouwer E., Tervaert J. W., Weening J. J., Kallenberg C. G. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int. 1998 Feb;53(2):253–263. doi: 10.1046/j.1523-1755.1998.00743.x. [DOI] [PubMed] [Google Scholar]
  17. Jayne D. R., Davies M. J., Fox C. J., Black C. M., Lockwood C. M. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991 May 11;337(8750):1137–1139. doi: 10.1016/0140-6736(91)92797-6. [DOI] [PubMed] [Google Scholar]
  18. Jayne D. R., Gaskin G., Pusey C. D., Lockwood C. M. ANCA and predicting relapse in systemic vasculitis. QJM. 1995 Feb;88(2):127–133. [PubMed] [Google Scholar]
  19. Jayne D. R., Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc. 1997 Aug;72(8):737–747. doi: 10.1016/S0025-6196(11)63594-5. [DOI] [PubMed] [Google Scholar]
  20. Jennette J. C., Falk R. J., Andrassy K., Bacon P. A., Churg J., Gross W. L., Hagen E. C., Hoffman G. S., Hunder G. G., Kallenberg C. G. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187–192. doi: 10.1002/art.1780370206. [DOI] [PubMed] [Google Scholar]
  21. Jennette J. C., Falk R. J. Small-vessel vasculitis. N Engl J Med. 1997 Nov 20;337(21):1512–1523. doi: 10.1056/NEJM199711203372106. [DOI] [PubMed] [Google Scholar]
  22. Lockwood C. M., Thiru S., Stewart S., Hale G., Isaacs J., Wraight P., Elliott J., Waldmann H. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM. 1996 Dec;89(12):903–912. doi: 10.1093/qjmed/89.12.903. [DOI] [PubMed] [Google Scholar]
  23. Lúdvíksson B. R., Sneller M. C., Chua K. S., Talar-Williams C., Langford C. A., Ehrhardt R. O., Fauci A. S., Strober W. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol. 1998 Apr 1;160(7):3602–3609. [PubMed] [Google Scholar]
  24. Pinching A. J., Rees A. J., Pussell B. A., Lockwood C. M., Mitchison R. S., Peters D. K. Relapses in Wegener's granulomatosis: the role of infection. Br Med J. 1980 Sep 27;281(6244):836–838. doi: 10.1136/bmj.281.6244.836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pusey C. D., Rees A. J., Evans D. J., Peters D. K., Lockwood C. M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991 Oct;40(4):757–763. doi: 10.1038/ki.1991.272. [DOI] [PubMed] [Google Scholar]
  26. Reumaux D., Vossebeld P. J., Roos D., Verhoeven A. J. Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood. 1995 Oct 15;86(8):3189–3195. [PubMed] [Google Scholar]
  27. Savage C. O., Gaskin G., Pusey C. D., Pearson J. D. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Exp Nephrol. 1993 May-Jun;1(3):190–195. [PubMed] [Google Scholar]
  28. Savage C. O., Harper L., Adu D. Primary systemic vasculitis. Lancet. 1997 Feb 22;349(9051):553–558. doi: 10.1016/s0140-6736(97)80118-3. [DOI] [PubMed] [Google Scholar]
  29. Schmitt W. H., Heesen C., Csernok E., Rautmann A., Gross W. L. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum. 1992 Sep;35(9):1088–1096. doi: 10.1002/art.1780350914. [DOI] [PubMed] [Google Scholar]
  30. Sibelius U., Hattar K., Schenkel A., Noll T., Csernok E., Gross W. L., Mayet W. J., Piper H. M., Seeger W., Grimminger F. Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J Exp Med. 1998 Feb 16;187(4):497–503. doi: 10.1084/jem.187.4.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Simpson I. J., Skinner M. A., Geursen A., Peake J. S., Abbott W. G., Fraser J. D., Lockwood C. M., Tan P. L. Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis. Clin Exp Immunol. 1995 Aug;101(2):220–226. doi: 10.1111/j.1365-2249.1995.tb08342.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sitara D., Hoffbrand B. I. Chronic bronchial suppuration and antineutrophil cytoplasmic antibody (ANCA) positive systemic vasculitis. Postgrad Med J. 1990 Aug;66(778):669–671. doi: 10.1136/pgmj.66.778.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Stegeman C. A., Tervaert J. W., Huitema M. G., Kallenberg C. G. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol. 1993 Mar;91(3):415–420. doi: 10.1111/j.1365-2249.1993.tb05918.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Stegeman C. A., Tervaert J. W., Kallenberg C. G. Anti-neutrophil cytoplasmic antibodies: tools for diagnosis and follow-up in systemic vasculitis. Ann Med Interne (Paris) 1994;145(8):523–532. [PubMed] [Google Scholar]
  35. Stegeman C. A., Tervaert J. W., de Jong P. E., Kallenberg C. G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996 Jul 4;335(1):16–20. doi: 10.1056/NEJM199607043350103. [DOI] [PubMed] [Google Scholar]
  36. Tervaert J. W., Huitema M. G., Hené R. J., Sluiter W. J., The T. H., van der Hem G. K., Kallenberg C. G. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 1990 Sep 22;336(8717):709–711. doi: 10.1016/0140-6736(90)92205-v. [DOI] [PubMed] [Google Scholar]
  37. Vogt B. A., Kim Y., Jennette J. C., Falk R. J., Burke B. A., Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr. 1994 Jun;124(6):986–988. doi: 10.1016/s0022-3476(05)83199-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES